Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Identifieur interne : 005629 ( Main/Exploration ); précédent : 005628; suivant : 005630Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Auteurs : Murat Emre [États-Unis] ; Werner Poewe ; Peter Paul De Deyn ; Paolo Barone ; Jaime Kulisevsky ; Emmanuelle Pourcher ; Teus Van Laar ; Alexander Storch ; Federico Micheli ; David Burn ; Frank Durif ; Rajesh Pahwa ; Francesca Callegari ; Nadia Tenenbaum ; Christine StrohmaierSource :
- Clinical neuropharmacology [ 1537-162X ]
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Analysis of Variance, Dementia (drug therapy), Dementia (etiology), Drug Carriers, Drug Delivery Systems, Female, Humans, International Cooperation, Longitudinal Studies, Male, Middle Aged, Neuroprotective Agents (therapeutic use), Outcome Assessment (Health Care), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Patient Compliance, Phenylcarbamates (therapeutic use), Quality of Life, Rivastigmine, Time Factors, Transdermal Patch, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Neuroprotective Agents, Phenylcarbamates.
- chemical : Drug Carriers, Rivastigmine.
- complications : Parkinson Disease.
- drug therapy : Dementia, Parkinson Disease.
- etiology : Dementia.
- psychology : Parkinson Disease.
- Aged, Aged, 80 and over, Analysis of Variance, Drug Delivery Systems, Female, Humans, International Cooperation, Longitudinal Studies, Male, Middle Aged, Outcome Assessment (Health Care), Patient Compliance, Quality of Life, Time Factors, Transdermal Patch, Treatment Outcome.
Abstract
This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.
DOI: 10.1097/WNF.0000000000000010
PubMed: 24434526
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000804
- to stream PubMed, to step Curation: 000804
- to stream PubMed, to step Checkpoint: 000804
- to stream Ncbi, to step Merge: 001664
- to stream Ncbi, to step Curation: 001664
- to stream Ncbi, to step Checkpoint: 001664
- to stream Main, to step Merge: 006046
- to stream Main, to step Curation: 005629
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.</title><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation wicri:level="2"><nlm:affiliation>*Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; †Department of Neurology, Medical University Innsbruck, Innsbruck, Austria; ‡Middelheim Hospital, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; §Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; ║Neurodegenerative Diseases Centre, Department of Medicine, University of Salerno, Italy; ¶Department of Neurology, Movement Disorders Unit, Hospital de Sant Pau (IIB-Sant Pau) and CIBERNED, Universitat Autònoma de Barcelona, Barcelona, Spain; #Québec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne, Québec, Canada; **Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany; ††Department of Neurology, Hospital de Clinicas, University of Buenos Aires, Argentina; ‡‡Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom; §§Service De Neurologie CHU, Clermont-Ferrand, France; ║║Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, KS; ¶¶Novartis Pharma AG, Basel, Switzerland; and ##Novartis Pharmaceuticals Corporation, East Hanover, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>*Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; †Department of Neurology, Medical University Innsbruck, Innsbruck, Austria; ‡Middelheim Hospital, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; §Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; ║Neurodegenerative Diseases Centre, Department of Medicine, University of Salerno, Italy; ¶Department of Neurology, Movement Disorders Unit, Hospital de Sant Pau (IIB-Sant Pau) and CIBERNED, Universitat Autònoma de Barcelona, Barcelona, Spain; #Québec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne, Québec, Canada; **Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany; ††Department of Neurology, Hospital de Clinicas, University of Buenos Aires, Argentina; ‡‡Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom; §§Service De Neurologie CHU, Clermont-Ferrand, France; ║║Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, KS; ¶¶Novartis Pharma AG, Basel, Switzerland; and ##Novartis Pharmaceuticals Corporation, East Hanover</wicri:cityArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation></affiliation></author><author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name></author><author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name></author><author><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name></author><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name></author><author><name sortKey="Durif, Frank" sort="Durif, Frank" uniqKey="Durif F" first="Frank" last="Durif">Frank Durif</name></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name></author><author><name sortKey="Callegari, Francesca" sort="Callegari, Francesca" uniqKey="Callegari F" first="Francesca" last="Callegari">Francesca Callegari</name></author><author><name sortKey="Tenenbaum, Nadia" sort="Tenenbaum, Nadia" uniqKey="Tenenbaum N" first="Nadia" last="Tenenbaum">Nadia Tenenbaum</name></author><author><name sortKey="Strohmaier, Christine" sort="Strohmaier, Christine" uniqKey="Strohmaier C" first="Christine" last="Strohmaier">Christine Strohmaier</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2014 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:24434526</idno><idno type="pmid">24434526</idno><idno type="doi">10.1097/WNF.0000000000000010</idno><idno type="wicri:Area/PubMed/Corpus">000804</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000804</idno><idno type="wicri:Area/PubMed/Curation">000804</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000804</idno><idno type="wicri:Area/PubMed/Checkpoint">000804</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000804</idno><idno type="wicri:Area/Ncbi/Merge">001664</idno><idno type="wicri:Area/Ncbi/Curation">001664</idno><idno type="wicri:Area/Ncbi/Checkpoint">001664</idno><idno type="wicri:Area/Main/Merge">006046</idno><idno type="wicri:Area/Main/Curation">005629</idno><idno type="wicri:Area/Main/Exploration">005629</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.</title><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation wicri:level="2"><nlm:affiliation>*Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; †Department of Neurology, Medical University Innsbruck, Innsbruck, Austria; ‡Middelheim Hospital, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; §Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; ║Neurodegenerative Diseases Centre, Department of Medicine, University of Salerno, Italy; ¶Department of Neurology, Movement Disorders Unit, Hospital de Sant Pau (IIB-Sant Pau) and CIBERNED, Universitat Autònoma de Barcelona, Barcelona, Spain; #Québec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne, Québec, Canada; **Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany; ††Department of Neurology, Hospital de Clinicas, University of Buenos Aires, Argentina; ‡‡Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom; §§Service De Neurologie CHU, Clermont-Ferrand, France; ║║Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, KS; ¶¶Novartis Pharma AG, Basel, Switzerland; and ##Novartis Pharmaceuticals Corporation, East Hanover, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>*Department of Neurology, Behavioural Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; †Department of Neurology, Medical University Innsbruck, Innsbruck, Austria; ‡Middelheim Hospital, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; §Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; ║Neurodegenerative Diseases Centre, Department of Medicine, University of Salerno, Italy; ¶Department of Neurology, Movement Disorders Unit, Hospital de Sant Pau (IIB-Sant Pau) and CIBERNED, Universitat Autònoma de Barcelona, Barcelona, Spain; #Québec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne, Québec, Canada; **Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany; ††Department of Neurology, Hospital de Clinicas, University of Buenos Aires, Argentina; ‡‡Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom; §§Service De Neurologie CHU, Clermont-Ferrand, France; ║║Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, KS; ¶¶Novartis Pharma AG, Basel, Switzerland; and ##Novartis Pharmaceuticals Corporation, East Hanover</wicri:cityArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation></affiliation></author><author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name></author><author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name></author><author><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name></author><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name></author><author><name sortKey="Durif, Frank" sort="Durif, Frank" uniqKey="Durif F" first="Frank" last="Durif">Frank Durif</name></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name></author><author><name sortKey="Callegari, Francesca" sort="Callegari, Francesca" uniqKey="Callegari F" first="Francesca" last="Callegari">Francesca Callegari</name></author><author><name sortKey="Tenenbaum, Nadia" sort="Tenenbaum, Nadia" uniqKey="Tenenbaum N" first="Nadia" last="Tenenbaum">Nadia Tenenbaum</name></author><author><name sortKey="Strohmaier, Christine" sort="Strohmaier, Christine" uniqKey="Strohmaier C" first="Christine" last="Strohmaier">Christine Strohmaier</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="eISSN">1537-162X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Dementia (drug therapy)</term><term>Dementia (etiology)</term><term>Drug Carriers</term><term>Drug Delivery Systems</term><term>Female</term><term>Humans</term><term>International Cooperation</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (therapeutic use)</term><term>Outcome Assessment (Health Care)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Patient Compliance</term><term>Phenylcarbamates (therapeutic use)</term><term>Quality of Life</term><term>Rivastigmine</term><term>Time Factors</term><term>Transdermal Patch</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Phenylcarbamates</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Carriers</term><term>Rivastigmine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dementia</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Drug Delivery Systems</term><term>Female</term><term>Humans</term><term>International Cooperation</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Outcome Assessment (Health Care)</term><term>Patient Compliance</term><term>Quality of Life</term><term>Time Factors</term><term>Transdermal Patch</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>New Jersey</li></region></list><tree><noCountry><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><name sortKey="Callegari, Francesca" sort="Callegari, Francesca" uniqKey="Callegari F" first="Francesca" last="Callegari">Francesca Callegari</name><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name><name sortKey="Durif, Frank" sort="Durif, Frank" uniqKey="Durif F" first="Frank" last="Durif">Frank Durif</name><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name><name sortKey="Strohmaier, Christine" sort="Strohmaier, Christine" uniqKey="Strohmaier C" first="Christine" last="Strohmaier">Christine Strohmaier</name><name sortKey="Tenenbaum, Nadia" sort="Tenenbaum, Nadia" uniqKey="Tenenbaum N" first="Nadia" last="Tenenbaum">Nadia Tenenbaum</name><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></noCountry><country name="États-Unis"><region name="New Jersey"><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005629 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005629 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24434526
|texte= Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24434526" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |